Alpelisib Pill

Phase 2Small molecule

TTianjin Medical University Second Hospital

Alpelisib Pill is one of 43 small molecule programs targeting Treatment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TreatmentRecruiting

Endometroid Endometrial CancerActive, not recruiting

TreatmentPhase 2

Recruiting

Endometroid Endometrial CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

332 competitors in Treatment

#DrugCompanyPhaseTrials

Biltricide

Bayer

Preclinical

3 2

Dexilant

Takeda

Preclinical

2 3

Niclocide

Bayer

Preclinical

1 4

Minipress

Pfizer

Preclinical

1 5

Theo-Dur

Pfizer

Preclinical

1 6

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 7

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 8

Alpelisib Pill

TTianjin Medical University Second Hospital

Phase 2

1 9

Clomid

Ferring

Preclinical

1 10

Lotemax

PPharmos

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Treatment

NCT06739395

Q4 2028

Phase 2Active, not recruiting

Endometroid Endometrial Cancer

NCT05154487

Clinical

Trials by Indication[1]

Treatment1 trial

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Recruiting·TTianjin Medical University Second Hospital·Phase 2·NCT06739395·300 enrolled

Endometroid Endometrial Cancer1 trial

Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-Positive Endometrioid Endometrial Cancers

Active, not recruiting·GGOG Foundation·Phase 2·NCT05154487·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Alpelisib Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alpelisib Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alpelisib Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tianjin Medical University Second Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTianjin Medical University Second Hospital

Alpelisib Pill

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2028

Trials by Indication[1]

Treatment1 trial

Endometroid Endometrial Cancer1 trial

References

Drug Info

Quick Facts

Related News